Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Moleculin Biotech, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 23 | 1 | 22 | 0 |
| Shares | 1.48M | 89 | 389.7K | −1.09M (−73.6%) |
| Value | $1.44M | $87 | $117.9K | −$1.32M (−91.8%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 59,278 | $18.0K | 0.00% |
| UBS Group AG | 7,989 | $2.41K | 0.00% |
| Stone House Investment Management, LLC | 3,300 | $996 | 0.00% |
| Atlantic Union Bankshares Corp | 379 | $115 | 0.00% |
Sold out (4)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Armistice Capital, LLC | 1,250,000 | $1.22M |
| Cetera Investment Advisers | 70,000 | $68.2K |
| Barclays PLC | 344 | $335 |
| FMR LLC | 34 | $33 |
Not filed for Q2 2025 yet (1)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Sandy Spring Bank | 89 | $87 |